ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
July 21 2021 - 6:00AM
Business Wire
ICON plc (NASDAQ: ICLR) (“ICON”), a
world-leading healthcare intelligence and clinical research
organisation, today announced that all resolutions at the Annual
General Meeting of the Company (AGM) held on July 20, 2021 (which
resolutions had all been recommended by the Board) were all duly
passed by shareholders. These resolutions were set out in the
Notice of the AGM sent to shareholders dated June 16, 2021 and are
available on the ICON plc website.
Forms of Proxy were received by ICON plc before the meeting,
appointing proxies and giving them the following voting
instructions:
RESOLUTION NUMBER
RESOLUTION
TOTAL NUMBER OF VOTES
VOTE FOR
VOTE AGAINST
VOTE WITHHELD
1.1
To re-elect Mr. Ciaran
Murray
45,442,486
43,550,051
1,877,670
14,765
1.2
To re-elect Ms. Joan Garahy
45,442,486
45,384,011
43,920
14,555
1.3
To re-elect Mr. Eugene
McCague
45,442,486
41,502,872
1,287,437
2,652,177
2.1
To elect Mr Colin Shannon
45,442,486
45,383,112
44,270
15,104
2.2
To elect Dr. Linda Grais
45,442,486
40,034,813
5,392,732
14,941
3
To receive accounts and
reports
45,442,486
45,387,374
2,453
52,659
4
To authorise the fixing of the
auditors’ remuneration
45,442,486
40,668,597
4,757,041
16,848
5
To authorise the Company to allot
shares
45,442,486
44,650,315
774,763
17,408
6**
To disapply pre-emption
rights
45,442,486
45,315,550
103,174
23,762
7**
To disapply pre-emption rights
for funding capital investment or acquisitions
45,442,486
45,299,002
119,991
23,493
8**
To authorise the Company to make
market purchases of shares
45,442,486
45,235,016
142,259
65,211
9**
To authorise the price range at
which the Company can reissue shares it holds as treasury
shares
45,442,486
45,172,229
117,834
152,423
** Special Resolution. All resolutions are ordinary resolutions
unless otherwise stated.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, the impact of
COVID-19 on our business, as well as other economic and global
market conditions and other risks and uncertainties detailed from
time to time in SEC reports filed by ICON, all of which are
difficult to predict and some of which are beyond our control. For
these reasons, you should not place undue reliance on these
forward-looking statements when making investment decisions. The
word "expected" and variations of such words and similar
expressions are intended to identify forward-looking statements.
Forward-looking statements are only as of the date they are made
and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information,
future events or otherwise. More information about the risks and
uncertainties relating to these forward-looking statements may be
found in SEC reports filed by ICON, including its Form 20-F, F-1,
S-8 and F-3, which are available on the SEC's website at
http://www.sec.gov.
ICON plc is a world-leading healthcare intelligence and clinical
research organisation. From molecule to medicine, we advance
clinical research providing outsourced services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. We develop new innovations, drive emerging therapies
forward and improve patient lives. With headquarters in Dublin,
Ireland, ICON employed approximately 16,480 employees in 89
locations in 45 countries as at June 30, 2021. For further
information about ICON, visit: www.iconplc.com and
www.iconplc.com/pra.
Source: ICON plc
ICON/ICLR-F
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210721005443/en/
Investor Relations 1 888 381 7923 Brendan Brennan Chief
Financial Officer + 353 1 291 2000 Jonathan Curtain Vice President
Corporate Finance and Investor Relations + 353 1 291 2000
All at ICON.
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Aug 2024 to Sep 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Sep 2023 to Sep 2024